These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16515390)

  • 21. Thrombus formation at the surface of guide-wire models: effects of heparin-releasing or heparin-exposing surface coatings.
    Aldenhoff YB; Hanssen JH; Knetsch ML; Koole LH
    J Vasc Interv Radiol; 2007 Mar; 18(3):419-25. PubMed ID: 17377189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coils and tubes releasing heparin. Studies on a new vascular graft prototype.
    Aldenhoff YB; Knetsch ML; Hanssen JH; Lindhout T; Wielders SJ; Koole LH
    Biomaterials; 2004 Jul; 25(16):3125-33. PubMed ID: 14980407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of systemic anticoagulation in patients undergoing angioaccess surgery.
    D'Ayala M; Smith RM; Martone C; Briggs W; Deitch JS; Wise L
    Ann Vasc Surg; 2008 Jan; 22(1):11-5. PubMed ID: 18055171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
    Montalescot G; Walenga JM
    Clin Appl Thromb Hemost; 2009; 15(2):183-96. PubMed ID: 19117960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of heparin-coated stents in neurovascular interventional procedures: preliminary experience with 10 patients.
    Parkinson RJ; Demers CP; Adel JG; Levy EI; Sauvageau E; Hanel RA; Shaibani A; Guterman LR; Hopkins LN; Batjer HH; Bendok BR
    Neurosurgery; 2006 Oct; 59(4):812-21; discussion 821. PubMed ID: 17038945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stent thrombosis with drug-eluting stents: a re-examination of the evidence.
    Kedia G; Lee MS
    Catheter Cardiovasc Interv; 2007 May; 69(6):782-9. PubMed ID: 17394249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods to evaluate the pharmacology of oral antiplatelet drugs.
    Weber AA; Adamzik M; Bachmann HS; Görlinger K; Grandoch M; Leineweber K; Müller-Beissenhirtz H; Wenzel F; Naber C;
    Herz; 2008 Jun; 33(4):287-96. PubMed ID: 18581078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced thrombogenicity of nitinol stents--in vitro evaluation of different surface modifications and coatings.
    Tepe G; Schmehl J; Wendel HP; Schaffner S; Heller S; Gianotti M; Claussen CD; Duda SH
    Biomaterials; 2006 Feb; 27(4):643-50. PubMed ID: 16095686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular risk associated with interruption of antiplatelet and oral anticoagulation therapy.
    Ferreira JS; Gil VM
    Rev Port Cardiol; 2009; 28(7-8):845-58. PubMed ID: 19894663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
    Denardo SJ; Davis KE; Tcheng JE
    Am J Cardiol; 2007 Nov; 100(9):1376-82. PubMed ID: 17950793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-eluting stent thrombosis.
    Stähli BE; Camici GG; Tanner FC
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):45-52. PubMed ID: 19124388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Surgical procedures in patients treated with platelet function inhibitors].
    Rupprecht HJ; Blank R; Konradi D; Andreas K; Auerbach H
    Herz; 2008 Jun; 33(4):254-9. PubMed ID: 18581074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients.
    Miglionico M; Patti G; D'Ambrosio A; Di Sciascio G
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):600-4. PubMed ID: 18360849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer.
    Lee YK; Hyung Park J; Tae Moon H; Yun Lee D; Han Yun J; Byun Y
    Biomaterials; 2007 Mar; 28(8):1523-30. PubMed ID: 17157376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry.
    Rubboli A; Bolognese L; Di Pasquale G; Galvani M; La Vecchia L; Maggioni AP
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):200-3. PubMed ID: 19377385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double jeopardy: balance between bleeding and stent thrombosis with prolonged dual antiplatelet therapy after drug-eluting stent implantation.
    Yan BP; Gurvitch R; Ajani AE
    Cardiovasc Revasc Med; 2006; 7(3):155-8. PubMed ID: 16945822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coronary stents: a materials perspective.
    Mani G; Feldman MD; Patel D; Agrawal CM
    Biomaterials; 2007 Mar; 28(9):1689-710. PubMed ID: 17188349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
    Ducrocq G; Serebruany V; Tanguay JF
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.